AMGN Stock Recent News

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQ: AMGN) on behalf of long-term stockholders following a class action complaint that was filed against Amgen on March 13, 2023 with a Class Period from July 29, 2020 and April 27, 2022. Our investigation concerns whether the board of directors of Amgen have breached their fiduciary duties to the company.

Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.

Amgen Inc. (NASDAQ:AMGN ) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ET Company Participants Jay Bradner - Executive Vice President and Head, R&D Justin Claeys - Vice President, IR Conference Call Participants Yaron Werber - TD Cowen Yaron Werber Well, good morning everybody, and thanks once again for joining us at the 45th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team and it's a great pleasure to moderate the next fireside chat with Amgen.

Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market.  MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly, which are weekly injectables.

THOUSAND OAKS, Calif. , March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025.

Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding its single share price, making it a 'safer' buy. Analysts project net gains of 13.06% to 37.60% from the top ten Dow Dogs by March 2026, with average gains estimated at 23.59%. Six more 'safer' Dividend Dow Dogs are close to meeting the ideal dividend-to-price ratio, including Cisco, Chevron, and Procter & Gamble.

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif. , March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for surgery and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) compared to placebo.1,2 The data were published today in the New England Journal of Medicine  and were highlighted as a late-breaking oral presentation during the American Academy of Allergy Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego.

THOUSAND OAKS, Calif. , Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m.